Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

Adagio Therapeutics Inc.

NAS: ADGI

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Adagio Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Jun 7, 2023, 7:11 p.m.

ADGI
/zigman2/quotes/228559245/composite

$

1.37

Change

-0.0100 -0.72%

Volume

Volume 13,691

Quotes are delayed by 20 min

/zigman2/quotes/228559245/composite

Previous close

$ 1.41

$ 1.38

Change

-0.03 -2.13%

Day low

Day high

$1.36

$1.43

Open

52 week low

52 week high

$1.03

$4.90

Open

Company Description

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibo...

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Valuation

Price to Book Ratio

0.46

Enterprise Value to EBITDA

0.87

Efficiency

Liquidity

Current Ratio

15.06

Quick Ratio

15.06

Cash Ratio

14.86

Profitability

Return on Assets

-48.11

Return on Equity

-52.81

Return on Total Capital

-53.10

Capital Structure

Total Debt to Total Assets

0.97

Officers and Executives

Name Age Officer Since Title
Mr. David Hering 46 2021 Chief Operating Officer
Mr. Jeremy Gowler - 2022 Chief Operating Officer
Mr. Frederick W. Driscoll 70 2022 Chief Financial & Accounting Officer
Ms. Stacy Price - 2023 Chief Technology & Manufacturing Officer
Dr. Robert D. Allen - 2023 Chief Scientific Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/01/2022 David Hering
Chief Executive Officer; Director 		8,000   Acquisition at $4.52 per share. 36,160
08/19/2022 M28 Capital Management LP
Director 		584,451   Acquisition at $4.62 per share. 2,700,163
08/18/2022 M28 Capital Management LP
Director 		1,265,549   Acquisition at $4.31 per share. 5,454,516
08/17/2022 M28 Capital Management LP
Director 		1,000,000   Acquisition at $4.04 per share. 4,040,000
03/03/2022 Adimab LLC
1,158,089   0
08/10/2021 Adimab LLC
25,860,700   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Mithril Capital Management LLC
9,244,580   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
320,160   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
4,755,460   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
28,520   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
19,540   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
55,595   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Polaris Growth Management LLC
2,852,425   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Redmile Group LLC
1,920,960   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2021 Mithril Capital Management LLC
1,997,000   Acquisition at $17 per share. 33,949,000
08/10/2021 Polaris Growth Management LLC
177,500   Acquisition at $17 per share. 3,017,500
08/10/2021 Polaris Growth Management LLC
45,000   Acquisition at $17 per share. 765,000
08/10/2021 Polaris Growth Management LLC
2,678   Acquisition at $17 per share. 45,526
08/10/2021 Polaris Growth Management LLC
1,834   Acquisition at $17 per share. 31,178
08/10/2021 Polaris Growth Management LLC
5,219   Acquisition at $17 per share. 88,723
08/10/2021 Polaris Growth Management LLC
267,769   Acquisition at $17 per share. 4,552,073
08/10/2021 Redmile Group LLC
1,470,000   Acquisition at $17 per share. 24,990,000
/news/latest/company/us/adgi

MarketWatch News on ADGI

  1. Biotech Stocks Are Still Falling. The Near-Term Outlook Is Grim.

    10:21 a.m. May 2, 2022

    - Barron's Online

  4. Adagio Stock Spikes on New Data, but Its Omicron Problems Remain

    9:33 a.m. March 30, 2022

    - Barron's Online

  8. Adagio Therapeutics downgraded to underweight at Morgan Stanley

    11:45 a.m. Jan. 6, 2022

    - Tomi Kilgore

  9. Adagio Therapeutics downgraded to hold from buy at Stifel, price target slashed to $9 from $50

    10:25 a.m. Dec. 15, 2021

    - Tonya Garcia

  13. Adagio Therapeutics upgraded to overweight at Morgan Stanley

    10:30 a.m. Nov. 29, 2021

    - Tomi Kilgore

  15. Adagio Therapeutics started at buy with $57 stock price target at Stifel Nicolaus

    7:30 a.m. Aug. 31, 2021

    - Tomi Kilgore

  16. The IPO Market Is on Break. Adagio Is Friday's Only Deal.

    4:32 p.m. Aug. 6, 2021

    - Barron's Online

  19. Adagio Therapeutics sets IPO terms, to be valued at up to $1.8 bln

    6:38 a.m. Aug. 2, 2021

    - Tomi Kilgore

/news/nonmarketwatch/company/us/adgi

Other News on ADGI

  1. 10-Q: INVIVYD, INC.

    4:23 p.m. May 11, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-K: INVIVYD, INC.

    4:33 p.m. March 23, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  4. 10-Q: INVIVYD, INC.

    6:10 p.m. Nov. 10, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  5. Invivyd Names Fred Driscoll as Interim CFO, Cuts Some Positions

    4:52 p.m. Oct. 13, 2022

    - The Wall Street Journal Interactive Edition

  6. 10-Q: ADAGIO THERAPEUTICS, INC.

    8:12 a.m. Aug. 15, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  7. Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies

    12:14 p.m. March 31, 2022

    - Zacks.com

  8. Why Adagio Therapeutics Stock Is Soaring Today

    10:50 a.m. March 30, 2022

    - Motley Fool

  9. These 2 Nasdaq Biotech Stocks Are Soaring Wednesday Morning

    8:24 a.m. March 30, 2022

    - Motley Fool

At a Glance

Invivyd, Inc.

1601 Trapelo Road

Suite 178

Waltham, Massachusetts 02451

Phone

1 7818190080

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

N/A

Net Income

$-241.32M

Employees

84.00

Annual Report for ADGI

/news/pressrelease/company/us/adgi

Press Releases on ADGI

  14. Invivyd Shareholder Action Reminder

    8:37 a.m. April 2, 2023

    - Newsfile Corp

  21. Loading more headlines...
Link to MarketWatch's Slice.